IGF2 is a potential factor in RAI‑refractory differentiated thyroid cancer

Differentiated thyroid cancer (DTC) is the most frequent endocrine tumor with a good prognosis after primary treatment in cases. By contrast, 30‑40% of patients metastatic DTC are unresponsive to 131I radioactive iodide (RAI) due dedifferentiation. Currently, underlying molecular mechanisms dedifferentiation remain elusive and predictive biomarkers lacking. Therefore, present study aimed identify tumors associated RAI refractoriness. A retrospective cohort was gathered consisting RAI‑sensitive RAI‑refractory poorly DTC. In all patients, extensive intratumoral mutation profiling, gene fusions analysis, telomerase reverse transcriptase (TERT) promoter analysis formalin‑fixed paraffin‑embedded‑compatible RNA sequencing were performed. Genetic analyses revealed an increased mutational load DTC, including mutations AKT1, PTEN, TP53 TERT promoter. Transcriptomic profound differential expression insulin‑like growth factor 2 (IGF2), up 100‑fold higher compared ELISA significant lower IGF2 plasma concentrations surgery subsequent therapy pretreatment baseline. Overall, current findings suggested that tumor‑promoting may have potential role acquiring